Porous paclitaxel matrices and methods of manufacture thereof
US6610317B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 2, 2001 |
| Grant date | Aug 26, 2003 |
| Priority date | — |
| Expiry date | Mar 2, 2021 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S977/906
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Paclitaxel is provided in a porous matrix form, which allows the drug to be formulated without Cremophor and administered as a bolus. The paclitaxel matrices preferably are made using a process that includes (i) dissolving paclitaxel in a volatile solvent to form a paclitaxel solution, (ii) combining at least one pore forming agent with the paclitaxel solution to form an emulsion, suspension, or second solution, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of paclitaxel. The pore forming agent can be either a volatile liquid that is immiscible with the paclitaxel solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. In a preferred embodiment, microparticles of the porous paclitaxel matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.